

AREXVY Billing and Coding: Quick Reference Guide

The Following Includes Vaccine Product Codes and Some Common Administration Codes Associated With Immunization Using AREXVY

Vaccine administration codes are dependent on the services provided. Please refer to the latest edition of the Current Procedural Terminology (CPT) for appropriate administration codes, and the latest edition of International Classification of Diseases (ICD) manual for appropriate diagnosis codes.

How Supplied

AREXVY is supplied as 2 components: A single-dose vial of lyophilized antigen component (powder) and a single-dose vial of adjuvant suspension component (liquid) (packaged without syringes or needles)¹

Dosage

A single dose after reconstitution is 0.5 mL¹

Coding for AREXVY

CPT Code (Product)	90679
CPT Code (Administration) ²	90471: 1 vaccine administered 90472: Each additional vaccine administered during same encounter
ICD-10-CM Code ^{3*}	Z23: Encounter for immunization
MVX Code ⁴	SKB
CVX Code ⁵	303

NDCs¹

Outer Carton (Supplied as package of 10 doses)	10-Digit: 58160-848-11 11-Digit: 58160-0848-11 [†]
--	--

*ICD-10-CM code Z23, Encounter for Immunization, is reported for all vaccines given within an encounter; additional ICD-10-CM coding may be needed.³

[†]Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC.⁶

Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY

Please see additional Important Safety Information on next page and full [Prescribing Information](#) for AREXVY.

Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

Important Safety Information (cont'd)

- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- The most commonly reported adverse reactions ($\geq 10\%$) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- Vaccination with AREXVY may not result in protection of all vaccine recipients

References: 1. Prescribing Information for AREXVY. 2. American Medical Association. CPT category I new vaccine codes (including incorporation of ACIP abbreviations listings) long descriptors. Accessed April 21, 2023. <https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf> 3. Centers for Medicare and Medicaid Services. 2023 ICD-10-CM official guidelines for coding and reporting. Accessed April 21, 2023. <https://www.cms.gov/files/document/fy-2023-icd-10-cm-coding-guidelines-updated-01/11/2023.pdf> 4. Centers for Disease Control and Prevention. Immunization information systems (IIS): HL7 standard code set, MVX – manufacturers of vaccines. Accessed April 21, 2023. <https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=mvx> 5. Centers for Disease Control and Prevention. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. Accessed April 21, 2023. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx> 6. Humana Military. Office injectable guidelines, national drug code (NDC) pricing and filing tips. Accessed April 21, 2023. <https://www.humanamilitary.com/provider/education-and-resources/claims/office-injectable>

Please see additional Important Safety Information on previous page and full Prescribing Information for AREXVY.

Trademarks are owned by or licensed to the GSK group of companies.



©2023 GSK or licensor.
RSALBND230011 May 2023
Produced in USA.